[Neurology].
In 2011, new oral anticoagulants for atrial fibrillation are available and the ABCD3-I score predicting stroke after TIA updates the ABCD2 score. New McDonald criteria allow faster MS diagnosis and the first oral treatment (fingolimod) for MS can be prescribed. A new anti-antiepileptic drug (retigabine) is available and sodium valproate has long term neurological adverse effects after in utero exposure. Among Parkinson disease treatments, deep brain stimulation is extending applications and dopamine agonists with extended release are as efficient and well tolerated as standard forms at long term scale. Monoclonal antibodies and immunosuppressant agents are proposed as good alternatives in the treatment of chronic dysimmune polyneuropathies. Gene therapy for the treatment of genetic myopathies is progressing.
Service de neurologie, Département de neurosciences cliniques, CHUV, Lausanne. jo.nsimy@gmail.com
J N
JN
Chabwine
A R
AR
Rossetti
L
L
Hirt
T
T
Kuntzer
M
M
Schluep
P
P
Michel
J F
JF
Démonet
R A
RA
du Pasquier
F G
FG
Vingerhoets
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use; D002908:Chronic Disease; D046690:Deep Brain Stimulation; D018491:Dopamine Agonists / Q000627:therapeutic use; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy; D000068876:Fingolimod Hydrochloride; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy; D009135:Muscular Diseases / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D009462:Neurology / Q000639:trends; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy; D010655:Phenylenediamines / Q000627:therapeutic use; D011115:Polyneuropathies / Q000175:diagnosis / Q000188:drug therapy; D011409:Propylene Glycols / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000927:Anticonvulsants; D002219:Carbamates; D018491:Dopamine Agonists; D007166:Immunosuppressive Agents; D010655:Phenylenediamines; D011409:Propylene Glycols; C101866:ezogabine; D014635:Valproic Acid; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine